Related references
Note: Only part of the references are listed.Antitumor responses in gastric cancer by targeting B7H3 via chimeric antigen receptor T cells
Fengqiang Sun et al.
CANCER CELL INTERNATIONAL (2022)
Immunotherapy for gastric cancer: a 2021 update
Christo Kole et al.
IMMUNOTHERAPY (2022)
The New Era of Immunotherapy in Gastric Cancer
Shogo Takei et al.
CANCERS (2022)
Immunotherapy in Gastric Cancer
Anica Hoegner et al.
CURRENT ONCOLOGY (2022)
Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues
Zijie Feng et al.
NATURE CANCER (2022)
Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
Sreya Bagchi et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 16, 2021 (2021)
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
Yelena Y. Janjigian et al.
NATURE (2021)
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Deborah Blythe Doroshow et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Immunotherapy of gastric cancer: Past, future perspective and challenges
Jun Xie et al.
PATHOLOGY RESEARCH AND PRACTICE (2021)
Gastrin Vaccine Alone and in Combination With an Immune Checkpoint Antibody Inhibits Growth and Metastases of Gastric Cancer
Jill P. Smith et al.
FRONTIERS IN ONCOLOGY (2021)
The role and application of small extracellular vesicles in gastric cancer
Hao Wu et al.
MOLECULAR CANCER (2021)
CAR-T cell therapy: current limitations and potential strategies
Robert C. Sterner et al.
BLOOD CANCER JOURNAL (2021)
Adoptive cell therapy for solid tumors: Chimeric antigen receptor T cells and beyond
Victor Moreno et al.
CURRENT OPINION IN PHARMACOLOGY (2021)
Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer
Bihui Cao et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2021)
Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Ronan J. Kelly et al.
CLINICAL CANCER RESEARCH (2020)
Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The Immune Microenvironment Impacts Survival in Western Patients with Gastric Adenocarcinoma
Abhineet Uppal et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2020)
Current status of immune checkpoint inhibitors for gastric cancer
Koji Kono et al.
GASTRIC CANCER (2020)
Integrated immune gene expression signature and molecular classification in gastric cancer: New insights
Maria Grazia Refolo et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2020)
Immune-related adverse events of checkpoint inhibitors
Manuel Ramos-Casals et al.
NATURE REVIEWS DISEASE PRIMERS (2020)
Recent advances in mRNA vaccine technology
Norbert Pardi et al.
CURRENT OPINION IN IMMUNOLOGY (2020)
CAR-T Cell Therapy-An Overview of Targets in Gastric Cancer
Dominika Bebnowska et al.
JOURNAL OF CLINICAL MEDICINE (2020)
mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer
Gal Cafri et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
Kohei Shitara et al.
JAMA ONCOLOGY (2020)
Esophageal, gastric cancer and immunotherapy: small steps in the right direction?
Adam Zayac et al.
TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Steering CAR T cells to distinguish friend from foe
Hillary G. Caruso et al.
ONCOIMMUNOLOGY (2019)
Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells
Lijun Liang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer
Jiang Lv et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Adoptive T-Cell Therapy for Cheek for Solid Malignancies
Mohammad S. Jafferji et al.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2019)
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial
Roy S. Herbst et al.
LANCET ONCOLOGY (2019)
Immunotherapy in advanced gastric cancer, is it the future?
C. Coutzac et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial
Toshihiko Doi et al.
GASTRIC CANCER (2019)
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
J. Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo
Yanjing Song et al.
PROTEIN & CELL (2018)
Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination with IgG1 antibody in patients with gastric or colorectal cancer
Takeshi Ishikawa et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Kohei Shitara et al.
LANCET (2018)
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Dal Fukurnura et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial
Charles S. Fuchs et al.
JAMA ONCOLOGY (2018)
Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
Y. -J. Bang et al.
ANNALS OF ONCOLOGY (2018)
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang et al.
LANCET (2017)
Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy
Xingchun Gao et al.
FRONTIERS IN IMMUNOLOGY (2017)
Gastric adenocarcinoma
Jaffer A. Ajani et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer
Yung-Jue Bang et al.
CLINICAL CANCER RESEARCH (2017)
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
Kei Muro et al.
LANCET ONCOLOGY (2016)
CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside
Qi Zhang et al.
ONCOIMMUNOLOGY (2016)
Toxicity and management in CAR T-cell therapy
Challice L. Bonifant et al.
MOLECULAR THERAPY-ONCOLYTICS (2016)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
Padmanee Sharma et al.
CELL (2015)
Cytokine-Induced Killer Cells Engineered with Exogenous T-Cell Receptors Directed Against Melanoma Antigens: Enhanced Efficacy of Effector Cells Endowed with a Double Mechanism of Tumor Recognition
Angela R. Elia et al.
HUMAN GENE THERAPY (2015)
Cancer Immunotherapy Researchers Focus on Refining Checkpoint Blockade Therapies
Julie A. Jacob
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Immune Checkpoint Blockade in Cancer Therapy
Michael A. Postow et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
The Experimental Study on the Treatment of Cytokine-Induced Killer Cells Combined with EGFR Monoclonal Antibody Against Gastric Cancer
Lin Zhang et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2014)
Multivariate Statistical Data Analysis as a Tool to Analyze Ex Vivo Expansion Dynamics of Cytokine-Induced Killer Cells
Cristina Zanon et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2014)
Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer
Mitsuru Sasako et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Cancer immunotherapy comes of age
Ira Mellman et al.
NATURE (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients
Jing-Ting Jiang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2010)
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses
Manish J. Butte et al.
IMMUNITY (2007)
Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length
Xinglei Shen et al.
JOURNAL OF IMMUNOTHERAPY (2007)
An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: The GC4 study
JA Ajani et al.
CANCER (2006)
Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study
Motoki Yoshida et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2004)
Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide
Y Sato et al.
CANCER SCIENCE (2003)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
HD Dong et al.
NATURE MEDICINE (2002)
Share Paper
